---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-113820"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T11:41:27.496507+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Personalis Q1 revenue $20.6M (+6% YoY); clinical test volume up 52% sequentially

## Summary
- Revenue $20.6M, up 6% YoY; pharma tests/services $13.6M (+39%), population sequencing $6.7M (-29%).
- Net loss $15.8M ($0.18/share) vs $13.0M ($0.26) in Q1 2024; per-share improved on higher share count.
- Clinical test volume 2,184, up 52% from Q4 2024; NeXT Personal data in CRC and breast cancer submitted for Medicare.
- Raised $17.8M net from ATM at $5.89/share; cash $185.7M; operations cash use $20.5M.
- FY2025 revenue guidance unchanged $80-90M; gross margin raised to 22%-24%; net loss guidance narrowed to ~$83M.

## SEC filing metadata
- accession: 0001193125-25-113820
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000119312525113820/0001193125-25-113820-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000119312525113820/d821404d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-113820
- JSON: https://secwatch.observer/filing/0001193125-25-113820.json
- Plain text: https://secwatch.observer/filing/0001193125-25-113820.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.